# A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

> **NCT04877990** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 67 (actual)

## Conditions studied

- Crohn Disease
- Ulcerative Colitis

## Interventions

- **DRUG:** Deucravacitinib

## Key facts

- **NCT ID:** NCT04877990
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-07
- **Primary completion:** 2023-08-29
- **Final completion:** 2023-08-29
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04877990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04877990, "A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04877990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*